Bladder Cancer Survival Better With Nivolumab Than Placebo in New Analysis. Neil Osterweil. February 21, 2025 . 0. Adjuvant therapy with nivolumab (Opdivo, “nivo”) continues to show disease ...

Immunotherapy with nivolumab (Opdivo) after surgery for metastatic bladder cancer significantly reduces the odds for the tumor's return, a new clinical trial finds. Among 700 patients with ...

The immune checkpoint blockade drug nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder cancer, regardless of whether their tumors had a biomarker related to the ...

New research from Memorial Sloan Kettering Cancer Center (MSK) medical oncologist Dean Bajorin, MD, and colleagues found that patients who received nivolumab (Opdivo®) after bladder cancer surgery ...

Adjuvant nivolumab extended DFS compared with placebo among patients with high-risk, muscle invasive urothelial carcinoma, according to results of the phase 3 CheckMate 274 trial presented at ...

ew research from Memorial Sloan Kettering Cancer Center (MSK) medical oncologist Dean Bajorin, MD, and colleagues found that patients who received nivolumab (Opdivo®) after bladder cancer surgery ...

7. McNulty R. FDA approves enfortumab vedotin plus pembrolizumab for locally advanced or metastatic bladder cancer. The American Journal of Managed Care website. December 18, 2023. Accessed March ...

To evaluate the activity and safety of nivolumab with nab-paclitaxel as neoadjuvant therapy, ... (RC) and postsurgical adjuvant nivolumab in patients with muscle-invasive bladder cancer (MIBC).

CheckMate 274 is a practice-changing study that led to FDA approval for adjuvant nivolumab in high-risk urothelial carcinoma, the most common bladder cancer histology.

Many more trials are in development in earlier disease states, testing agents such as MPDL3280A (NCT02302807) in the first-line setting in cisplatin-ineligible patients with metastatic bladder cancer, ...

During a live event, Sumanta K. Pal, MD, discussed second-line renal cell carcinoma therapies, in the context of a patient ...

--CG Oncology, Inc., a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer ...